Ethyl pyruvate decreased early nuclear factor-κB levels but worsened survival in lipopolysaccharide-challenged mice

Critical Care Medicine

Volumn 36, Issue 4, 2008, Pages 1059-1067

  Su, Junwu ^a,b   Li, Xuemei ^a,c   Cui, Xizhong ^a   Li, Yan ^a   Fitz, Yvonne ^a   Hsu, Lewis ^d   Mani, Haresh ^a   Quezado, Martha ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Ethyl pyruvate; Lipopolysaccharide; Sepsis; Treatment

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; PHOSPHATE; PLACEBO; PYRUVIC ACID DERIVATIVE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; HAZARD RATIO; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; STATISTICAL SIGNIFICANCE; SURVIVAL;

EID: 41649094479     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCM.0B013E318164403B     Document Type: Article

References (49)

1. O'Donnell-Torney J, Nathan CF, Lanks K, et al: Secretion of pyruvate: An antioxidant defense of mammalian cells. J Exp Med 1987; 165:500-514
2. Salahudeen AK, Clark EC, Nath KA: Hydrogen peroxide-induced renal injury: A protective role for pyruvate in vitro and in vivo. J Clin Invest 1991; 88:1886-1893
3. Brand KA, Hermfisse U: Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species. FASEB J 1997; 11:388-395
4. Borle AB, Stank RT: Pyruvate reduces anoxic injury and free radical formation in perfused rat hepatocytes. Am J Physiol 1996; 270:G535-G540
5. Biagini GA, Park JH, Lloyd D, et al: The antioxidant potential of pyruvate in the amitochondriate diplomonads Giardia intestinalis and Hexamita inflata. Microbiology 2001; 147:3359-3365
6. Deboer LW, Bekx PA, Han L, et al: Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. Am J Physiol 1993; 265:H1571-H1576
7. Pierpaolo S, Stefano S, Sergio M, et al: Pyruvate inhibits hepatic ischemia-reperfusion injury in rats. Transplantation 2001; 72:27-30
8. Mongan PD, Fontana JL, Chen R, et al: Intravenous pyruvate prolongs survival during hemorrhagic shock in swine. Am J Physiol 1999; 277:H2253-H2263
9. Mongan PD, Capacchione J, Fontana JL, et al: Pyruvate improves cerebral metabolism during hemorrhagic shock. Am J Physiol Heart Circ Physiol 2001; 281:H854-H864
10. Willems JL, de Kort AFM, Vreea TB, et al: Non-enzymatic conversion of pyruvate in aqueous solution to 2,4-dihydroxy-2-methylglutaric acid. FEBS Lett 1978; 86:42-44
11. Sims CA, Wattanasirichaigoon S, Menconi MJ, et al: Ringer's ethyl-pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med 2001; 29:1513-1518
12. Yang R, Gallo DJ, Baust JJ, et al: Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 2002; 283:G212-G221
13. Tawadrous ZS, Delude RL, Fink MP: Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock 2002; 17:1262-1269
14. Uchiyama T, Delude RL, Fink MP: Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med 2003; 29:2050-2058
15. Yang R, Han X, Delude RL, et al: Ethyl pyruvate ameliorates alcohol-induced liver injury and inflammation in mice. J Lab Clin Med 2003; 142:322-331
16. Yang R, Uchiyama T, Watkins SK, et al: Ethyl pyruvate reduces liver injury in a murine model of extrahepatic cholestasis. Shock 2004; 22:369-375
17. Harada T, Moore BA, Yang R, et al: Ethyl pyruvate ameliorates ileus induced by bowel manipulation in mice. Surgery 2005; 138:530-537
18. Tsung A, Kaizu T, Nakao A, et al: Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation 2005; 79:196-204
19. Han Y, Engelert JA, Yang R, et al: Ethyl pyruvate inhibits NF-κB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther 2005; 312:1097-1115
20. Venkataraman R, Kellum JA, Song M, et al: Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock 2002; 18:507-512
21. Ulloa L, Ochani M, Yang H, et al: Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Nat Acad Sci U S A 2002; 99:351-356
22. Yang R, Uchiyama T, Alber SM, et al: Ethyl pyruvate ameliorates distant organ injury in a murine model of necrotizing pancreatitis. Crit Care Med 2004; 32:1453-1459
23. Sappington PL, Cruz RJ, Harada T, et al: The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidacrylate, and methyl-2-acetamidacrylate, exhibit anti-inflammatory properties in vivo and/or in vitro. Biochem Pharmacol 2005; 70:1579-1592
24. Sappington PL, Han X, Yang R, et al: Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated Caco-2 enterocytic monolayers. J Pharmacol Exp Ther 2003; 304:464-476
25. Hauser B, Kick J, Asfar P, et al: Ethyl pyruvate improves systemic and hepatosplanchnic hemodynamics and prevents lipid peroxidation in a porcine model of resuscitated hyperdynamic endotoxemia. Crit Care Med 2005; 33:2034-2042
26. Ajami AM, Sims CA, Fink MP: Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion. US Patent Number 6,846,842
27. Fink MP, Ulloa L, Tracey KJ, et al: Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. US Patent No. 6,943, 190
28. Critical Therapeutics Announces Decision to Discontinue Trial of CTI-01, Daily Updates. Available at: http://www.leaddiscovery.co.uk/pr/ Critical_Therapeutics_Announces_Decision_to_Discontinue_Clinical_Trial_of_CTI- 01.html. Accessed July 9, 2007
29. Andersson A, Fenhammmar J, Frithiof R, et al: Haemodynamic and metabolic effects of resuscitation with Ringer's ethyl pyruvate in acute phase of porcine endotoxaemic shock. Acta Anaesthesiol Scand 2006; 50:1198-1206
30. Mulier KE, Beilman GJ, Conroy MJ, et al: Ringer's ethyl pyruvate in hemorrhagic shock and resuscitation does not improve early hemodynamics or tissue energetics. Shock 2005; 23:248-252
31. Senftleben U, Li ZW, Baud V, et al: IKKβ is essential for protecting T cells from TNFα. Immunity 2001; 14:217-230
32. Lawrence T, Gilroy DW, Colville-Nash PR, et al: Possible new role of NF-κB in the resolution of inflammation. Nat Med 2001; 7:1291-1297
33. Chen L, Egan L, Li ZW, et al: The two faces of IKK and NF-κB inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003; 9:575-581
34. Li X, Cui X, Li Y, et al: Parthenolide has limited effects of nuclear factor-κB increases and worsens survival in lipopolysaccharide-challenged C57BL/6J mice. Cytokine 2006; 33:299-308
35. Freeman BD, Correa R, Karzai W, et al: Controlled trial of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats. J Appl Physiol 1996; 80:2066-2076
36. Lieberthal W, Nigam SK: Acure renal failure: II. Experimental models of acute renal failure: Imperfect but indispensable. Am J Physiol Renal Physiol 2000; 278:F1-F12
37. Eichacker PQ, Parent C, Kalil A, et al: Risk and the efficacy of anti-inflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166:1197-1205
38. Cui X, Parent C, Macarthur H, et al: Severity of sepsis alters the effects of superoxide anion inhibition in a rat sepsis model. J Appl Physiol 2004; 97:1349-1357
39. Shao YM, Yao HG, Liang XZ, et al: Relation between level of expression of high mobility group protein B1 in hepatic tissue with the severity and prognosis of sepsis in the rat. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2006; 18:668-672
40. Su F, Wang Z, Cai Y, et al: Beneficial effects of ethyl pyruvate in septic shock from peritonitis. Arch Surg 2007; 142:166-171
41. Stehlik C, dwe Martin R, Binder BR, et al: Cytokine induced expression of porcine inhibitor of apoptosis protein (IAP) family member is regulated by NF-κB. Biochem Biophys Res Commun 1998; 243:827-832
42. Piva R, Belardo G, Santoro MG: NF-κB: A stress-regulated switch for cell survival. Antioxid Redox Signal 2006; 8:478-486
43. Kisseleva T, Song L, Vorontchikhinia M, et al: NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancer. J Clin Invest 2006; 116:2955-2963
44. Gadjeva M, Tomczak MF, Zhang M, et al: A role of NF-κB subunits p50 and p65 in the inhibition of lipopolysaccharide-induced shock. J Immunol 2004; 173:5786-5793
45. Miyaji T, Hu X, Yuen PST, et al: Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 2003; 64:1620-1631
46. Sheehan M, Wong HR, Hake PW, et al: Parthenolide, an inhibitor of the NF-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic rodents. Mol Pharmacol 2002; 61:953-963
47. Sheehan M, Wong HR, Hake PW, et al: Protective effects of isohelenin, an inhibitor of NF-κB, in endotoxic shock in rats. J Endotoxin Res 2002; 8:99-107
48. Fink MP: Nuclear factor-kappaB: Is it a therapeutic target for the adjuvant treatment of sepsis? Crit Care Med 2003; 31:2400 -2402
49. Zingarelli B: Ethyl pyruvate: A simple solution? Crit Care Med 2004; 2004:1603-1604